Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589453077> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2589453077 endingPage "261" @default.
- W2589453077 startingPage "261" @default.
- W2589453077 abstract "261 Background: Over 155,000 women are living with metastatic breast cancer (mBC) in the US. Chemotherapies can prolong survival for women with mBC, but adverse events (AEs) stemming from their use are common and costly to manage. We compared the healthcare costs for taxane- (TAX) and capecitabine-based (CAP) treatments for mBCpatients as either first- or second-line (FL or SL) therapy in the US. Methods: Using the Marketscan Commercial Database, a nationally representative database of over 52 million people, we selected mBC patients diagnosed from 2008-2011. Patients were categorized into FL and SL chemotherapy including either a TAX (paclitaxel or docetaxel) or CAP using an algorithm based on pharmacy and medical claims data. Chemotherapy-related AEs were identified by ICD-9 codes. Costs were tabulated from a payer perspective. Average monthly costs were stratified by treatment and the presence/absence of AEs. Results: Among 15,535 mBCpatients we identified 15,472 FL and 6,809 SL cases treated with TAX or CAP. The mean age of patients was 51 years (SD 8). At least one AE was experienced during FL treatment by 74% (SD 44%) and 68% (SD 46%) of TAX and CAP users and during SL treatment 60% (SD 49%) and 59% (SD 49%), respectively. Average monthly total costs during the FL period were $2,385 higher (p <0.0001) and $1,679 higher (p=0.28) for TAX- and CAP-treated patients who experienced at least one AE. In SL, costs for patients with at least one AE had were $2,995 (p<0.0001) higher for TAX-treated patients and $4,870 (p=0.0026) higher for CAP-treated patients. Conclusions: Among community-treated patients, AEs are common in women with mBC receiving TAX- and CAP-based chemotherapy regimens. These AEs are associated with higher costs in FL and SL. When possible, prevention or earlier management of AEs may represent an opportunity to reduce costs and improve outcomes for women with mBC. [Table: see text]" @default.
- W2589453077 created "2017-03-03" @default.
- W2589453077 creator A5032187510 @default.
- W2589453077 creator A5032325756 @default.
- W2589453077 creator A5046985026 @default.
- W2589453077 creator A5047960113 @default.
- W2589453077 creator A5068059897 @default.
- W2589453077 creator A5072015843 @default.
- W2589453077 creator A5078803157 @default.
- W2589453077 date "2013-11-01" @default.
- W2589453077 modified "2023-10-03" @default.
- W2589453077 title "The cost of adverse events in metastatic breast cancer in taxane- and capecitabine-based regimens." @default.
- W2589453077 doi "https://doi.org/10.1200/jco.2013.31.31_suppl.261" @default.
- W2589453077 hasPublicationYear "2013" @default.
- W2589453077 type Work @default.
- W2589453077 sameAs 2589453077 @default.
- W2589453077 citedByCount "0" @default.
- W2589453077 crossrefType "journal-article" @default.
- W2589453077 hasAuthorship W2589453077A5032187510 @default.
- W2589453077 hasAuthorship W2589453077A5032325756 @default.
- W2589453077 hasAuthorship W2589453077A5046985026 @default.
- W2589453077 hasAuthorship W2589453077A5047960113 @default.
- W2589453077 hasAuthorship W2589453077A5068059897 @default.
- W2589453077 hasAuthorship W2589453077A5072015843 @default.
- W2589453077 hasAuthorship W2589453077A5078803157 @default.
- W2589453077 hasConcept C104863432 @default.
- W2589453077 hasConcept C121608353 @default.
- W2589453077 hasConcept C126322002 @default.
- W2589453077 hasConcept C143998085 @default.
- W2589453077 hasConcept C197934379 @default.
- W2589453077 hasConcept C2775930923 @default.
- W2589453077 hasConcept C2776694085 @default.
- W2589453077 hasConcept C2777511904 @default.
- W2589453077 hasConcept C2777909004 @default.
- W2589453077 hasConcept C2781190966 @default.
- W2589453077 hasConcept C512399662 @default.
- W2589453077 hasConcept C526805850 @default.
- W2589453077 hasConcept C530470458 @default.
- W2589453077 hasConcept C71924100 @default.
- W2589453077 hasConceptScore W2589453077C104863432 @default.
- W2589453077 hasConceptScore W2589453077C121608353 @default.
- W2589453077 hasConceptScore W2589453077C126322002 @default.
- W2589453077 hasConceptScore W2589453077C143998085 @default.
- W2589453077 hasConceptScore W2589453077C197934379 @default.
- W2589453077 hasConceptScore W2589453077C2775930923 @default.
- W2589453077 hasConceptScore W2589453077C2776694085 @default.
- W2589453077 hasConceptScore W2589453077C2777511904 @default.
- W2589453077 hasConceptScore W2589453077C2777909004 @default.
- W2589453077 hasConceptScore W2589453077C2781190966 @default.
- W2589453077 hasConceptScore W2589453077C512399662 @default.
- W2589453077 hasConceptScore W2589453077C526805850 @default.
- W2589453077 hasConceptScore W2589453077C530470458 @default.
- W2589453077 hasConceptScore W2589453077C71924100 @default.
- W2589453077 hasIssue "31_suppl" @default.
- W2589453077 hasLocation W25894530771 @default.
- W2589453077 hasOpenAccess W2589453077 @default.
- W2589453077 hasPrimaryLocation W25894530771 @default.
- W2589453077 hasRelatedWork W181195935 @default.
- W2589453077 hasRelatedWork W2024302667 @default.
- W2589453077 hasRelatedWork W2058292467 @default.
- W2589453077 hasRelatedWork W2085123446 @default.
- W2589453077 hasRelatedWork W2135287852 @default.
- W2589453077 hasRelatedWork W2406160662 @default.
- W2589453077 hasRelatedWork W2589453077 @default.
- W2589453077 hasRelatedWork W3041235120 @default.
- W2589453077 hasRelatedWork W4232088779 @default.
- W2589453077 hasRelatedWork W4253360580 @default.
- W2589453077 hasVolume "31" @default.
- W2589453077 isParatext "false" @default.
- W2589453077 isRetracted "false" @default.
- W2589453077 magId "2589453077" @default.
- W2589453077 workType "article" @default.